Its sales practices have left it fighting bribery charges in China. And now GlaxoSmithKline wants to move on. The UK drugs company will stop paying doctors to promote its products at events. And it'll also remove individual sales targets for its marketing staff. That's a step further than AstraZeneca which two years ago stopped paying healthcare professionals to attend medical conferences. IG's Alistair McCaig says GSK could suffer financially as a result.